Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients

(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news